The cell surface receptor Siglec-6 is highly expressed on human mast cells and represents a promising therapeutic target for mast cell disorders. The siglec family of proteins comprises carbohydrate-binding receptors, most of which exert inhibitory effects on immune cells and several of which have been investigated as targets through which to deliver payload drugs/toxins to specific cells via receptor endocytosis. However, there have been no publications regarding Siglec-6 function or endocytosis in human mast cells. Because there is currently no curative treatment for systemic mastocytosis and most symptom-based treatments focus on mast cell mediators rather than mast cell activation, Siglec-6-targeted treatments have the potential to significantly improve patient prognosis and quality of life.
|Effective start/end date||7/1/17 → 6/30/19|
- American Academy of Allergy, Asthma and Immunology (Agreement 05/01/17)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.